Department: Management

Marc Hedrick

Dr. Marc Hedrick is the President and CEO at Plus Therapeutics, Inc.  Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc.  Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA).  Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA.

Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.

Andrew Sims

Andrew Sims is Vice President and Chief Financial Officer at Plus Therapeutics, Inc.  Mr. Sims arrived at Plus Therapeutics having previously held Chief Financial Officer roles at several private equity-backed companies. His focus has been on mergers and acquisitions, integrations, corporate capitalization, and building out and managing teams to support global growth. Previously, Mr. Sims was Partner at Mazars, a global accounting, advisory, audit, tax and consulting firm. Working from both the Oxford, England and New York offices, Mr. Sims audited and advised global public clients, including a variety of healthcare companies, with average annual revenues in excess of $1 billion. Further, he was the lead partner on over 50 acquisitions ranging from $5 million to $4 billion in purchase price.

Mr. Sims is a native of the United Kingdom and is now a proud U.S. citizen.  He is a Certified Public Accountant in the U.S. and a Chartered Accountant in England and Wales. He is a graduate of Buckingham University in the United Kingdom.

Russ Havranek

Russ Havranek is the Vice President of Corporate Strategy and New Product Planning at Plus Therapeutics, Inc.  He was previously Vice President of Global Marketing and Business Development at Cytori Therapeutics.

Mr. Havranek has over 26 years of leadership experience developing and commercializing diagnostic and therapeutic products at global, publicly traded, biopharma and medical device companies. His prior roles in marketing, strategy, business development, general management, and R&D focused on the oncology, rare disease, cardiology, and orthopedic markets.  These roles were held at Johnson & Johnson, Guidant (now Abbott), Genentech (now Roche), DJO Global (now Enovis), Volcano (now Philips), and CareFusion (now Becton Dickinson).

Mr. Havranek received a MBA in Marketing from the Haas School of Business at the University of California, Berkeley, a MS in Bioengineering from Clemson University, and a BS in Biomedical Engineering from Northwestern University.

Navin Parwani

Navin is the Vice President of Regulatory Affairs and Quality Affairs at Plus Therapeutics. Navin is a dynamic leader who brings over 24 years of strategic and leadership expertise in Regulatory Affairs and Quality Assurance, specializing in Biotechnology, Pharma, Diagnostics, and Medical Devices. He is known for his vision, innovation, and ability to lead high-performing teams in regulated environments. Navin has successfully executed regulatory strategies that have driven the commercialization of cutting-edge therapeutics and technologies, including oncology, urology, AI-based in vitro diagnostics, as well as complex medical devices.  Before joining Plus, Navin served as the head of Regulatory and Quality at Ikena Oncology, Taris (J&J) and Medtronic. His leadership was crucial during two major acquisitions by big Pharma, Johnson & Johnson, and Medtronic, as well as during two IPOs, where he established regulatory and quality functions from scratch.

Navin has been the primary interface with global regulatory bodies for several years, managing successful IND, NDA, 510(k), and PMA submissions and approvals, pre-approval inspections (PAIs), and regulatory audits across the USA, EU, and globally. He has led multiple teams through FDA warning letter remediation and quality remediation projects, achieving compliance and significant certifications, including CLIA and ISO 13485, and managing approval of class 2 and class 3 medical devices. Navin holds multiple master’s degrees, in Drug Discovery & Development and in Systems Engineering from Rutgers University.  Outside of work, he is a proud father, a soccer coach, and enjoys hiking, reading fiction, and exploring new technologies.

In his role at Plus therapeutics, Navin aims to leverage his extensive experience in leading regulatory and quality initiatives to solve complex challenges and drive innovation in medical technologies. His expertise in oncology therapeutics and diagnostics, combined with a proven track record in product development, achieving regulatory approvals and quality compliance will be key in advancing Plus’ nuclear medicine treatments. Navin is dedicated to ensuring the highest standards of safety and efficacy, positioning the organization as a leader in cancer treatment and diagnostics.